300+ investors in your industry, stage, and region Get
Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Malawi
Nepal
Mexico
Liberia
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Puerto Rico
Poland
China
Guernsey
Cameroon
Colombia
Armenia
Costa Rica
Kuwait
Czech Republic
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Botswana
Moldova
Seychelles
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
Germany
India
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Angola
Albania
Europe
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Cyprus
Peru
Slovenia
San Marino
Ukraine
Spain
Qatar
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Sambrinvest, VC Fund

Sambrinvest

VC Fund

Gosselies, Belgium

Sambrinvest is an active venture capital player in the region of Charleroi - Thuin.

Total investments:
41
Last investment:
Lead investor:
10%

Last updated:

Industries Sambrinvest invests in

BiotechnologyHealth CareMedicalTherapeuticsPharmaceutical

Stages Sambrinvest invests in

SeedSeries ASeries BFunding RoundVenture - Series Unknown

Countries Sambrinvest invests in

BelgiumFranceSpainThe Netherlands

Round sizes

Seed $544k–$24MSeries A $1M–$49MSeries B $4.4M–$45M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Seed
$544k–$24M
Series A
$1M–$49M
Series B
$4.4M–$45M

Investment Focus

Industry

  • Biotechnology 16 (39%)
  • Health Care 14 (34%)
  • Medical 8 (20%)
  • Therapeutics 6 (15%)
  • Pharmaceutical 5 (12%)
See all 48 industries →

Stage

  • Seed 15 (37%)
  • Series A 10 (24%)
  • Series B 7 (17%)
  • Funding Round 3 (7%)
  • Venture - Series Unknown 2 (5%)
See all 7 stages →

Country

  • Belgium 25 (61%)
  • France 7 (17%)
  • Spain 1 (2%)
  • The Netherlands 1 (2%)

Team

NameTitleInvestmentsLinksEmail
Anne Prignon Managing Director
Managing Director Total investments: 1
Find email

Investments

CompanyDescriptionRoundLinks
Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction. $11.9M / Convertible Note / Sep 21, 2026
Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment. $12.6M / Series A / Jul 20, 2026
Vertical Compute offers chiplet-based technology that cuts data movement to achieve up to 80% energy savings. $42.9M / Seed / Mar 04, 2026
Enodia Therapeutics is a biotech company that provides transforming treatments for cancer, inflammation, and viral infection diseases. $24.2M / Seed / Jan 08, 2026
Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. $29.2M / Sep 25, 2025
Elkedonia is a biotech company dedicated to transforming antidepressant therapy. It aims to develop a groundbreaking antidepressant treatment that is accessible, fast-acting, and free from the risks of dependence, sedation, or psychotic effects. $12.9M / Seed / Jun 11, 2025
ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients. $57.2M / Series A / Nov 18, 2024
AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. Nov 11, 2024
AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. $10.6M / Series A / Nov 11, 2024
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance. $29.2M / Series A / Sep 18, 2023
See all 41 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Malawi
Nepal
Mexico
Liberia
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Puerto Rico
Poland
China
Guernsey
Cameroon
Colombia
Armenia
Costa Rica
Kuwait
Czech Republic
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Botswana
Moldova
Seychelles
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
Germany
India
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Angola
Albania
Europe
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Cyprus
Peru
Slovenia
San Marino
Ukraine
Spain
Qatar
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Sambrinvest invest in?

Sambrinvest invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 41 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does Sambrinvest invest in?

Sambrinvest typically joins rounds of $544k–$24M at Seed, $1M–$49M at Series A and $4.4M–$45M at Series B. These are whole funding-round sizes, not Sambrinvest's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Sambrinvest took part in.

How do I contact Sambrinvest?

Public channels for Sambrinvest include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Sambrinvest?

The team at Sambrinvest includes Anne Prignon (Managing Director). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Sambrinvest Sambrinvest Find emails